Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 31;3(4):1252-1261.
doi: 10.1002/jha2.559. eCollection 2022 Nov.

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database

Arleigh McCurdy  1 , Martha Louzada  2 , Christopher P Venner  3 , Alissa Visram  1 , Esther Masih-Khan  4   5 , Moustafa Kardjadj  5 , Victor H Jimenez-Zepeda  6 , Richard LeBlanc  7 , Michael Sebag  8 , Kevin Song  9 , Darrell White  10 , Hira Mian  11 , Julie Stakiw  12 , Anthony Reiman  13 , Muhammad Aslam  14 , Rami Kotb  15 , Engin Gul  5 , Donna Reece  4   5
Affiliations

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database

Arleigh McCurdy et al. EJHaem. .

Abstract

Carfilzomib is an active and commonly used treatment in patients with multiple myeloma (MM). Using the Canadian Myeloma Research Group Database, we performed a retrospective observational study of patients treated with carfilzomib for relapse of MM in a real-world setting in Canada between years 2007 and 2020. A total of 445 patients were included in this study: the doublet (Kd/p, n = 218) and triplets (KCd, n = 88; KRd, n = 99; KPd/p, n = 40). One hundred and twenty-two (27%) received carfilzomib-based treatment in line 2, 133 (30%) in line 3, 90 (20%) in line 4, and 100 (23%) in line 5 or higher. Carfilzomib was dosed weekly in 40% of patients and twice weekly in 60%. The overall response rate of the entire cohort was 57.7%, with 33.6% of patients achieving very good partial response or better. Median progression-free survival for the overall cohort was 6.3 months with overall survival 19.7 months. This study provides a benchmark for carfilzomib-based regimens in the real world, demonstrating that these regimens are effective in treating patients with relapsed MM.

Keywords: carfilzomib; multiple myeloma; real‐world data.

PubMed Disclaimer

Conflict of interest statement

Arleigh McCurdy: honoraria—BMS, Janssen, Amgen, Takeda, Sanofi, and GSK. Martha Louzada: honoraria—Janssen, BMS, Amgen, and Pfizer. Christopher P. Venner: honoraria—Janssen, Amgen, and Takeda; research funding—BMS and Amgen. Victor H. Jimenez‐Zepeda: honoraria—Janssen, Takeda, Merck, and BMS. Richard LeBlanc: membership on an entity's Board of Directors or advisory committees—BMS Canada, Janssen Inc., Amgen Canada, Takeda Canada, and Sanofi Canada. Michael Sebag: membership on an entity's Board of Directors or advisory committees—Janssen Inc., Amgen Canada, Takeda Canada, and BMS Canada. Kevin Song: research funding—BMS; honoraria—BMS, Janssen, Amgen, and Takeda. Darrell White: honoraria—Amgen, Antengene, BMS, Janssen, Karyopharm, Sanofi, and Takeda. Hira Mian: honoraria—BMS, Janssen, Amgen, Takeda, Sanofi, and GSK; awards—HHS Research Early Career Award from Hamilton Health Sciences Foundation; research funding—Janssen. Rami Kotb: research funding—Merck and Sanofi; ownership/share holder—Karyopharm; honoraria—BMS, Janssen, Takeda, Amgen, Sanofi, and Merck. Donna Reece: research funding—Otsuka, BMS, Janssen, Takeda, Merck, BMS, and Millennium; consultancy—BMS, Janssen, Amgen, Karyopharm, and Takeda; honoraria—BMS, Janssen, Amgen, Takeda, Sanofi, and GSK. All remaining authors have declared no financial or perceived conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Flow diagram showing selection of study patients between July 2009 and December 2020. CMRG‐DB, Canadian Myeloma Research Group Database
FIGURE 2
FIGURE 2
Carfilzomib usage in patients, n (percentage) outside clinical trials by (A) lines of treatment and (B) years of study period.
FIGURE 3
FIGURE 3
Response rates by regimen and line of treatment. Percentages based on evaluable patients. ORR, overall response rates; PR, partial response; VGPR, very good partial response
FIGURE 4
FIGURE 4
(A–D) Effectiveness by regimen and line of treatment.
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008.
    1. Spencer A, Lentzsch S, Weisel K, Avet‐Loiseau H, Mark TM, Spicka I, et al. Daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of castor. Blood. 2017;130:3145.
    1. Dimopoulos MA, San‐Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018;103:2088–96. 10.3324/haematol.2018.194282 - DOI - PMC - PubMed
    1. Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36:728–34. 10.1200/jco.2017.76.5032 - DOI - PubMed
    1. Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, et al. Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR. J Clin Oncol. 2018;36:8032. 10.1200/JCO.2018.36.15_suppl.8032 - DOI

LinkOut - more resources